NASDAQ:SERA - Nasdaq - US81749D1072 - Common Stock - Currency: USD
NASDAQ:SERA (4/22/2025, 3:58:55 PM)
3.475
+0.08 (+2.51%)
The current stock price of SERA is 3.475 USD. In the past month the price decreased by -10.55%. In the past year, price decreased by -68.47%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.17 | 307.29B | ||
AMGN | AMGEN INC | 14.05 | 149.69B | ||
GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1691.57 | 126.11B | ||
REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.02B | ||
ARGX | ARGENX SE - ADR | 322.75 | 36.66B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.76B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.27B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
NTRA | NATERA INC | N/A | 19.56B | ||
BIIB | BIOGEN INC | 7.22 | 17.40B |
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 57 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
SERA PROGNOSTICS INC-A
2749 E. Parleys Way, Suite 200
Salt Lake City UTAH US
CEO: Gregory C. Critchfield
Employees: 56
Company Website: https://www.seraprognostics.com/
Investor Relations: https://seraprognostics.com/investors/
Phone: 18015050278
The current stock price of SERA is 3.475 USD. The price increased by 2.51% in the last trading session.
The exchange symbol of SERA PROGNOSTICS INC-A is SERA and it is listed on the Nasdaq exchange.
SERA stock is listed on the Nasdaq exchange.
SERA PROGNOSTICS INC-A (SERA) has a market capitalization of 130.87M USD. This makes SERA a Micro Cap stock.
SERA PROGNOSTICS INC-A (SERA) currently has 56 employees.
SERA PROGNOSTICS INC-A (SERA) has a support level at 3.25 and a resistance level at 3.47. Check the full technical report for a detailed analysis of SERA support and resistance levels.
The Revenue of SERA PROGNOSTICS INC-A (SERA) is expected to grow by 763.64% in the next year. Check the estimates tab for more information on the SERA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SERA does not pay a dividend.
SERA PROGNOSTICS INC-A (SERA) will report earnings on 2025-05-07, after the market close.
SERA PROGNOSTICS INC-A (SERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
The outstanding short interest for SERA PROGNOSTICS INC-A (SERA) is 2.94% of its float. Check the ownership tab for more information on the SERA short interest.
ChartMill assigns a fundamental rating of 2 / 10 to SERA. SERA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SERA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 14.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.33% | ||
ROE | -68.82% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to SERA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -0.97% and a revenue growth 763.64% for SERA